SCHEMBL3538440

SCHEMBL3538440

COCc1ccc2[nH]nc(-c3nc4ccc(N5CCN(C)CC5)cc4[nH]3)c2c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 14/20 0.70
FLT1 P17948 5/20 0.70
KDR P35968 3/20 0.60
FGFR2 P21802 2/20 0.60
FGFR4 P22455 2/20 0.60
FGFR3 P22607 2/20 0.60
FLT3 P36888 2/20 0.60
PDGFRA P16234 1/20 0.60
CDK4 P11802 1/20 0.59
CCNA2 P20248 1/20 0.59
CCND1 P24385 1/20 0.59
CDK2 P24941 1/20 0.59
CCND3 P30281 1/20 0.59
ABL1 P00519 3/20 0.56
AURKA O14965 1/20 0.54
JAK2 O60674 1/20 0.54
PDGFRB P09619 1/20 0.54
BCR P11274 1/20 0.53
KDM4E B2RXH2 1/20 0.52
MEN1 O00255 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3538365 0.92 FGFR1 (0.70) FGFR1FLT1KDRFGFR2FGFR4
SCHEMBL3535721 0.91 FGFR1 (0.66) FGFR1FLT1KDRFGFR2FGFR4
SCHEMBL3536930 0.90 FGFR1 (0.70) FGFR1FLT1KDRFGFR2FGFR4
SCHEMBL3537858 0.85 ABL1 (0.79) FGFR1FLT1KDRABL1BCR
SCHEMBL31006250 0.84 FGFR1 (0.76) FGFR1FLT1KDRFGFR2FGFR4
SCHEMBL3535921 0.84 FGFR1 (0.76) FGFR1FLT1KDRFGFR2FGFR4
SCHEMBL3535549 0.83 FGFR1 (0.66) FGFR1FLT1KDRFGFR2FGFR4
SCHEMBL3536287 0.83 ABL1 (0.74) FGFR1FLT1KDRFGFR2FGFR4
SCHEMBL3537770 0.83 FGFR1 (0.70) FGFR1FLT1KDRFGFR2FGFR4
SCHEMBL3536992 0.82 FGFR1 (0.73) FGFR1FLT1KDRFGFR2FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK FGFR1 886/4885FLT1 2793/4885KDR 2852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.